Skip to main content

Table  8 Relation between hepcidin with BCLC, tumor number, and distant metastases in group II (cirrhotic patients with HCC) (n = 30)

From: Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma

 

N

Hepcidin (ng/ml)

Test of sig.

p

Mean ± SD

Median (min.–max.)

BCLC

 A

5

1.04 ± 0.12

1.02 (0.86–1.19)

H = 0.116

0.990

 B

5

1.02 ± 0.08

1.01 (0.96–1.16)

 C

7

1.44 ± 1.14

1.0 (0.82–4.0)

 D

13

1.10 ± 0.18

1.09 (0.88–1.45)

Tumor number

 1

10

1.40 ± 0.93

1.14 (0.88–4.0)

H = 4.870

0.182

 2

6

1.03 ± 0.17

1.0 (0.86–1.36)

 3

3

1.13 ± 0.15

1.09 (1.01–1.30)

 > 3

11

1.00 ± 0.10

0.98 (0.82–1.18)

Distant metastases

 No

27

1.17 ± 0.58

1.02 (0.82–4.0)

U = 24.0

0.283

 Yes

3

1.0 ± 0.08

0.96 (0.95–1.09)

  1. SD Standard deviation. H H for Kruskal-Wallis test. U Mann-Whitney test. p p-value for hepcidin with BCLC, tumor number, and distant metastases relation